Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05659901 · ClinicalTrials.gov registry record
Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease
A clinical trial of Pelizaeus-Merzbacher Disease, sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- 32
- Enrollment target
- 7
- Study locations
NCT05659901 is a study of Pelizaeus-Merzbacher Disease that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 32 participants. The trial reports 7 study locations across 2 states.
The verdict
NCT05659901, a study of Pelizaeus-Merzbacher Disease, is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- 32 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of the study is to prospectively assess longitudinal changes in proteolipid protein 1 (PLP1) protein, disease-related biomarkers in cerebral spinal fluid (CSF) and blood, neuroimaging parameters relevant to Pelizaeus-Merzbacher disease (PMD) and longitudinal changes in performance on clinical, participant, and caregiver-reported outcome assessments to inform the development of therapies for PMD.
Conditions Studied
Study Locations (7)
Other
- Ionis Investigative Site - Clermont-Ferrand
- Ionis Investigative Site - Le Kremlin-Bicêtre
- Ionis Investigative Site - Göttingen
- Ionis Investigative Site - Tel Aviv
- Ionis Investigative Site - Milan
- Ionis Investigative Site - Amsterdam
Pennsylvania
- Ionis Investigative Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2029-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05659901
The ClinicalTrials.gov registry entry for NCT05659901 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pelizaeus-Merzbacher Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05659901 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05659901 about?
NCT05659901 is a clinical study titled "Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease". The purpose of the study is to prospectively assess longitudinal changes in proteolipid protein 1 (PLP1) protein, disease-related biomarkers in cerebral spinal fluid (CSF) and blood, neuroimaging parameters relevant to Pelizaeus-Merzbacher disease (PMD) and longitudinal changes in performance on cli...
What is the current status of trial NCT05659901?
This trial is currently recruiting. The enrollment target is 32 participants. The study started on 2022-10-03. Estimated completion is 2029-03.
What conditions does trial NCT05659901 study?
This clinical trial studies the following conditions: Pelizaeus-Merzbacher Disease.
Who is sponsoring clinical trial NCT05659901?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05659901 being conducted?
This trial has 7 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pelizaeus-Merzbacher Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)
RECRUITING · Phase 1
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.